MARAbio
Bob Wassman is a highly experienced individual who currently holds several key positions in various companies within the healthcare and biotech industries. With a background in genetics, personalized medicine, and clinical development, Bob has worked in roles such as Chief Medical Officer, Director, and Board Member in organizations focused on rare diseases, companion diagnostics, and advanced biomarker diagnostics. Additionally, Bob has a strong educational background, graduating with a degree in Biology from Yale University and obtaining certifications in Managed Health Care and Medical Genetics from Harvard T.H. Chan School of Public Health and UCLA, respectively.
MARAbio
We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.